The pharmaceutical and biological industry rose 0.65% on January 9, and 1 individual stock rose to the limit

News on January 9, the Shanghai Index rose 0.
58%, and 28 industries in Shenwan's industry rose, of which the pharmaceutical and biological industry rose 0.
65%
on the 9th.
In terms of individual stocks, of the 463 stocks belonging to the industry, 278 rose on the 9th, and 1 rose to the limit; There were 166 decliners and 1 stop
.
As of the close of trading on January 9, the stock closed with a price limit of 23.
09 yuan, a turnover of 135 million, and a turnover rate of 10.
62%.

The analysis believes that the reasons for the stock's limit include biomedicine and antibacterial drugs
.
The company's main products include antibacterial drugs, anticholinergic and synthetic antispasmodics, antifungal drugs for the skin, and other products, mainly covering antibacterial drugs (β-lactams and quinolones), anticholinergic and synthetic antispasmodic drugs (trimebutine maleate), antifungal drugs for the skin and other pharmaceutical fields
.
Among them, quinolone antibacterial drugs are a synthetic antibacterial drug, which is one of
the widely used antibacterial drugs in clinical practice.
Recently, the market demand for norfloxacin and other drugs for the treatment of diarrhea has expanded, and norfloxacin is a fluoroquinolone antibacterial drug, which can hinder the growth and development of bones and is banned in minors
under 18 years old.
Can be used for bacterial diarrhea, viral diarrhea is ineffective
.
Xingqi Eye Medicine closed up nearly 10% on January 9, with a quotation of 145.
61 yuan, a turnover of 749 million, and a turnover rate of 7.
73%.

According to the data, Xingqi Eye Medicine is a domestic professional ophthalmic pharmaceutical manufacturer, which has been focusing on the field of ophthalmology and adhering to the path
of professional development.
On December 15, 2022, the company announced the positive results of the clinical trial of atropine sulfate eye drops to delay myopia progression in children, a randomized, double-blind, placebo-controlled, multicenter 1-year clinical trial called "The efficacy and safety of atropine sulfate eye drops in delaying myopia progression in children", the results showed that there was a statistically significant difference in the main efficacy indicators between the atropine sulfate eye drops group and the placebo group, and the atropine sulfate eye drops group was better than the placebo group and had a good safety profile.
Patients have good adherence to use
.
Up to now, there are no low-concentration atropine sulfate eye drops that delay the progression of myopia in children in China that have been approved for marketing
.
In addition to the above stocks, the top gainers on January 9 were Meinian Health, Guangshengtang, and Zhongsheng Pharmaceutical, which rose by 8.
01%, 6.
78% and 6.
66% respectively, in addition, Zejing Pharmaceutical, Propharmaceutical, Aoxiang Pharmaceutical, Shenzhou Cell, etc.
all rose by more than 5%.

From the perspective of capital flow on January 9, the net outflow of main funds in the pharmaceutical and biological industry on the 9th was 1.
247 billion yuan
.
According to industry statistics, according to the statistics of capital flow data, there are 173 stocks with a net inflow of funds in the industry, of which 9 have a net inflow of more than 30 million yuan, of which WuXi AppTec has the highest net inflow of funds, with a net inflow of 262 million yuan on the 9th, followed by Zhongsheng Pharmaceutical, with a net inflow of 145 million yuan, in addition, Meinian Health has a net inflow of 88.
5464 million yuan
。 Among the stocks with a net outflow of funds in the industry, there were 11 stocks with a net outflow of more than 50 million yuan on January 9, of which Tongrentang and Yiling Pharmaceutical ranked first, with a net outflow of 114 million yuan and 111 million yuan
respectively.
In addition, the net outflow of Kanglong Chemical, China Pharmaceutical, Cperi and Hengrui Pharmaceutical all exceeded 7,000 yuan
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.